---
canonical_name: HGH
alternate_names: Human Growth Hormone, Growth Hormone, GH, Somatropin, Somatotropin, rhGH, Recombinant Human Growth Hormone, Genotropin, Norditropin, Humatrope, Omnitrope, Saizen, Zomacton, Nutropin, Serostim
canonical_topic: HGH for Health & Longevity
short_topic_lc: hgh
creation_date: 2026-0924-1246
creator_ai_fullname: Opus 5.5
ep_keywords: Peptide Hormones, Biologics, Hormones
---

# HGH for Health & Longevity
<section id="top" markdown="1"></section>  
Evidence Review created on 09/24/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5.5  

**Also known as:** Human Growth Hormone, Growth Hormone, GH, Somatropin, Somatotropin, rhGH, Recombinant Human Growth Hormone, Genotropin, Norditropin, Humatrope, Omnitrope, Saizen, Zomacton, Nutropin, Serostim

  

## Motivation

<!-- The Motivation section was written only after all other sections of this review were completed, so that it reflects the full scope of the topic. -->

Human growth hormone (HGH) is the protein the pituitary gland releases to drive growth in childhood and, in adulthood, to maintain body composition. Its output falls steadily after early adulthood, and a manufactured version, administered by daily injection, has been promoted for decades as a way to restore a more youthful physique and vitality.

Interest surged after a widely publicized early study of older men reported more muscle, less fat and thicker skin after six months of injections, and clinics built around hormone restoration followed. At the same time, animals and people with naturally weak growth hormone activity often live long lives and rarely develop cancer or diabetes. That contrast raises a real question: does more of this hormone slow aging, or speed it?

This review examines what controlled human evidence shows about growth hormone injections for health-focused adults, both with and without a diagnosed shortage: the effects on body composition, the risks for blood sugar and long-term health, and how dosing, monitoring and sourcing shape that balance.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**

  

## Recommended Reading

This section lists expert articles and podcast episodes that give a high-level overview of growth hormone therapy and its relevance to aging.

<!-- Search statement: On 2026-09-24 a real-time web search was performed for "growth hormone" / "HGH" together with each priority expert (Peter Attia, Andrew Huberman, Rhonda Patrick, Chris Kresser, Life Extension, Lifespan.io), plus direct searches on foundmyfitness.com (site search), peterattiamd.com, hubermanlab.com, lifeextension.com, lifespan.io and chriskresser.com. Each candidate page was loaded to confirm it discusses growth hormone by name or through its primary downstream mediator (IGF-1) in substantial depth. Chris Kresser: no dedicated growth hormone article or episode was found; an on-site search shows growth hormone named only in passing (a guest remark in a podcast on hormone treatment), which was judged not to meet the depth requirement. -->

* [Did a recent study show we can reverse aging?](https://peterattiamd.com/190929/) - Peter Attia

  Attia critiques the TRIIM pilot of growth hormone plus DHEA (dehydroepiandrosterone, an adrenal hormone precursor) and metformin, arguing that a small, short study of nine men without a control group cannot show reversed aging.

* [How to Control Your Metabolism by Thyroid & Growth Hormone](https://www.hubermanlab.com/episode/how-to-control-your-metabolism-by-thyroid-and-growth-hormone) - Andrew Huberman

  Explains how sleep, exercise, heat and fasting shape natural growth hormone release and its downstream messenger IGF-1 (insulin-like growth factor 1, made mainly by the liver), and reviews prescription options and their risks.

* [The longevity advantage of genetic deficiencies in growth hormone/IGF-1 signaling](https://www.foundmyfitness.com/episodes/longevity-deficiencies-growth-hormone-igf-1) - Rhonda Patrick & Valter Longo

  Valter Longo describes Ecuadorians with growth hormone receptor defects who rarely develop cancer or diabetes, the central human argument against raising growth hormone signaling for longevity.

* [In a First, Biological Aging Reversed in Human Subjects](https://www.lifeextension.com/newsletter/2019/10/in-a-first-biological-aging-reversed-in-human-subjects) - Life Extension

  Summarizes the TRIIM pilot, where growth hormone plus DHEA and metformin coincided with thymus regrowth; Life Extension, a supplement seller, partly funded the trial.

* [Meta-Analysis Discovers Goldilocks Zone for IGF-1](https://www.lifespan.io/news/meta-analysis-discovers-goldilocks-zone-for-igf-1/) - Greg Gillispie

  Covers evidence that both low and high IGF-1, the hormone through which growth hormone acts, predict higher mortality, which frames how far growth hormone therapy can raise it.

No dedicated growth hormone content from Chris Kresser (chriskresser.com) was found; growth hormone appears there only as a passing remark in a podcast on hormone treatment, without the depth required for inclusion.

  

## Grokipedia

<!-- Search statement: grokipedia.com was searched on 2026-09-24 for "human growth hormone". Tier 1 (d-browser) loaded the site's search results directly, listing "Recombinant human growth hormone" as the top entry alongside "Somatropin", "Growth hormone therapy" and "Growth hormone". The "Recombinant human growth hormone" page was selected as the primary page for the manufactured therapeutic product and was confirmed to load via d-fetch. Further tiers were not needed. -->

[Recombinant human growth hormone](https://grokipedia.com/page/Recombinant_human_growth_hormone)

Overview of the manufactured hormone covering its bioengineering history, approved uses, dosing units (1 mg equals about 3 international units) and the cadaver-derived era it replaced.

  

## Examine

<!-- Search statement: examine.com was searched on 2026-09-24 for "growth hormone". Tier 1 (d-browser) returned a "Vercel Security Checkpoint" bot wall; tier 2 (d-fetch) returned HTTP 429; tier 3 (d-proxy-1) loaded the search results, listing the outcome page "Growth Hormone" (/outcomes/growth-hormone/) as the only dedicated page. Examine does not have an intervention page for prescription recombinant HGH; the outcome page is its primary growth hormone page and was loaded via d-proxy-1 to confirm content. -->

[Growth Hormone](https://examine.com/outcomes/growth-hormone/)

Examine's outcome page grades which supplements and lifestyle factors raise the body's own growth hormone (drawn from 33 trials); it does not evaluate injected prescription growth hormone itself.

  

## ConsumerLab

<!-- Search statement: consumerlab.com was searched on 2026-09-24 for "growth hormone". Tier 1 (d-browser) loaded the site search, which redirected to the topic page "Reviews and Information for Growth Hormone (HGH)". It listed a product review of HGH/IGF-1 supplements and the CL Answer "What are human growth hormone (HGH) supplements? What are the benefits? Are they safe?", which covers both injections and supplements and was selected as the primary page; it was confirmed to load via d-fetch. Further tiers were not needed. -->

[What are human growth hormone (HGH) supplements? What are the benefits? Are they safe?](https://www.consumerlab.com/answers/hgh/human-growth-hormone/)

Explains that growth hormone works only by injection, that oral, spray and homeopathic "HGH" products contain no hormone, and summarizes the side effects of injections.

  

## Systematic Reviews

This section lists systematic reviews and meta-analyses on growth hormone treatment in adults, covering both its claimed benefits and its principal risks.

<!-- Search statement: On 2026-09-24 PubMed was searched in real time for (growth hormone OR somatropin) with "systematic review OR meta-analysis", including queries restricted to aging, healthy elderly, adult growth hormone deficiency, athletic performance, glucose metabolism, cancer and mortality. Selection prioritized relevance to adults, study size, recency and citation impact, and deliberately included reviews on both the claimed benefit (body composition, function, fractures) and the principal risks (glucose metabolism, mortality and cancer). -->

* [Systematic review: the safety and efficacy of growth hormone in the healthy elderly](https://pubmed.ncbi.nlm.nih.gov/17227934/) - Liu et al., 2007

  Pooled 18 randomized study populations of healthy older adults: about 2 kg lean gain and fat loss, with more swelling, joint pain and glucose problems.

* [Growth hormone treatment in aged patients with comorbidities: A systematic review](https://pubmed.ncbi.nlm.nih.gov/38489867/) - Tausendfreund et al., 2024

  Eight randomized trials in adults over 65 with frailty, heart failure, osteoporosis or hip fracture reported body-composition and function gains with mild side effects.

* [Effects of growth hormone therapy on bone density and fracture risk in age-related osteoporosis in the absence of growth hormone deficiency: a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/29030774/) - Barake et al., 2018

  Randomized trials in postmenopausal women with osteoporosis found no bone density gain but fewer fractures with growth hormone.

* [Effect of long-term growth hormone replacement on glucose metabolism in adults with growth hormone deficiency: a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/32888174/) - Zhou et al., 2021

  Across 33 studies in hormone-deficient adults, fasting glucose, insulin and long-term glucose markers worsened during the first year of replacement.

* [Association between growth hormone therapy and mortality, cancer and cardiovascular risk: systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/24818783/) - Deodati et al., 2014

  Mostly childhood-treated cohorts showed slightly raised all-cause mortality and more cancers and second tumors; the authors flag confounding and bias.

  

## Mechanism of Action

HGH is a 191-amino-acid protein identical to the pituitary's own growth hormone (GH). It binds the GH receptor on liver, muscle, fat and bone cells and activates JAK2-STAT5 signaling (an enzyme-to-gene relay that switches on growth genes). The main result is liver production of IGF-1, which drives protein synthesis and cell growth through the PI3K-Akt-mTOR pathway (the cell's central growth and nutrient-sensing switch).

* **Direct GH actions:** fat breakdown, sodium and water retention by the kidneys, and reduced insulin sensitivity in liver and muscle, which explain both fat loss and rising blood glucose.
* **IGF-1 actions:** lean-tissue growth plus collagen and bone formation.

**Competing explanations:**

* **Restoration view:** replacing the somatopause (the gradual fall in GH output after early adulthood) would reverse age-related fat gain and muscle loss.
* **Longevity-restraint view:** long-lived GH-deficient mice and people with GH-receptor defects suggest that lower GH/IGF-1 signaling slows aging and cancer, so raising it trades short-term building-up for long-term risk.

**Pharmacology:**

* **Half-life:** about 20–30 minutes intravenously (into a vein) and 2–4 hours after subcutaneous (under-the-skin) injection; IGF-1 stays raised for roughly a day.
* **Selectivity:** GH receptor; human GH also activates the prolactin receptor.
* **Distribution:** mostly extracellular fluid; acts chiefly on liver, muscle, fat, bone and kidney.
* **Metabolism:** broken down by protein-cleaving enzymes in liver and kidney, not by CYP enzymes (the liver's cytochrome P450 drug-clearing family), though GH can raise activity of CYP3A4 (a liver enzyme that clears many drugs).

  

## Historical Context & Evolution

Human GH was first extracted from cadaver pituitary glands in the 1950s to treat short stature in children. That supply ended in 1985, when recipients developed Creutzfeldt-Jakob disease (a fatal brain infection caused by misfolded prion proteins), and bacterially produced recombinant GH replaced it. Approved uses expanded to adult growth hormone deficiency (AGHD, low GH output from pituitary disease, surgery or radiation, confirmed by stimulation testing), wasting caused by HIV (human immunodeficiency virus) and several childhood growth disorders.

Interest in healthy aging began with a 1990 study in which 12 men aged 61–81 gained 8.8% lean mass, lost 14.4% fat and gained 7.1% skin thickness over six months ([Rudman et al., 1990](https://pubmed.ncbi.nlm.nih.gov/2355952/)). That same year, US federal law (21 U.S.C. §333(e)) made distributing GH for aging a felony, yet hormone clinics and the American Academy of Anti-Aging Medicine (founded in 1992; its member clinics earn revenue prescribing hormones) promoted it widely.

Randomized controlled trials (RCTs, studies that assign treatment by chance) then tested the idea. They confirmed the body-composition shift but found no gains in strength or function and frequent side effects ([Papadakis et al., 1996](https://pubmed.ncbi.nlm.nih.gov/8633830/)). In parallel, dwarf mice lacking GH were found to live substantially longer ([Brown-Borg et al., 1996](https://pubmed.ncbi.nlm.nih.gov/8900272/)), and people with Laron syndrome (inherited GH-receptor resistance) showed very little cancer or diabetes ([Guevara-Aguirre et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21325617/)). What changed was the arrival of controlled human data and longevity genetics, not a final verdict: small combination trials targeting the thymus have reopened the question.

  

## Expected Benefits

<!-- Search statement: Before writing this section, a dedicated search for the full benefit profile of recombinant GH was performed on 2026-09-24 using PubMed (systematic reviews, meta-analyses and RCTs in healthy older adults, adults with GH deficiency, osteoporosis, heart failure, athletes and longevity-oriented trials), the Endocrine Society and AACE adult GHD guidelines, and expert sources (Peter Attia, Andrew Huberman, Life Extension, Lifespan.io, Examine, ConsumerLab). Claimed benefits reviewed included body composition, strength, exercise capacity, lipids, bone, heart failure, cognition, well-being, skin, wound healing, athletic performance, thymus/immune function and epigenetic age. -->

### High 🟩 🟩 🟩

#### Lean Mass Gain & Fat Loss

GH shifts body composition toward more lean tissue and less fat through fat breakdown and IGF-1-driven protein retention. A meta-analysis of randomized trials in healthy adults averaging 69 years confirmed the shift ([Liu et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17227934/)), as did a 131-person RCT in adults aged 65–88 ([Blackman et al., 2002](https://pubmed.ncbi.nlm.nih.gov/12425705/)). Part of the lean gain is retained water, and strength and endurance did not improve in healthy older men ([Papadakis et al., 1996](https://pubmed.ncbi.nlm.nih.gov/8633830/)).

**Magnitude:** Lean body mass +2.1 kg (95% CI, or confidence interval, the range likely to contain the true value: 1.3 to 2.9) and fat mass −2.1 kg (95% CI −2.8 to −1.35) versus no GH over an average 27 weeks in healthy older adults; lean mass +2.61 kg versus +0.04 kg with placebo in GH-deficient adults ([Newman et al., 2015](https://pubmed.ncbi.nlm.nih.gov/24810900/)).

#### Exercise Capacity in Confirmed Adult GH Deficiency

In adults with confirmed AGHD, replacement raises aerobic capacity and peak power. A meta-analysis pooled 11 double-blind RCTs with 268 patients ([Widdowson & Gibney, 2008](https://pubmed.ncbi.nlm.nih.gov/18697875/)). The same authors found no gain in thigh-muscle strength over about seven months ([Widdowson & Gibney, 2010](https://pubmed.ncbi.nlm.nih.gov/19769614/)). In healthy older men, VO2max (maximal oxygen uptake, a core fitness measure) rose significantly only when GH was combined with testosterone ([Blackman et al., 2002](https://pubmed.ncbi.nlm.nih.gov/12425705/)).

**Magnitude:** Standardized effect size (a unit-free measure; 0.2 is small, 0.5 moderate) +0.34 (95% CI 0.07 to 0.62) for maximal oxygen uptake and +0.40 (95% CI 0.06 to 0.74) for maximal power output.

#### Improved Cholesterol Profile in Confirmed Adult GH Deficiency

GH increases liver clearance of LDL (low-density lipoprotein, the main cholesterol carrier linked to artery plaque). A meta-analysis of 22 placebo-controlled RCTs in GH-deficient adults found reductions at both low and high doses ([Newman et al., 2015](https://pubmed.ncbi.nlm.nih.gov/24810900/)). In healthy older adults, total cholesterol fell, but not significantly after adjusting for body-composition change ([Liu et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17227934/)). No trial has shown fewer heart attacks.

**Magnitude:** LDL cholesterol −0.42 mmol/L (about −16 mg/dL) with GH versus −0.1 mmol/L with placebo; total cholesterol −0.38 mmol/L versus +0.01 mmol/L.

#### Higher Bone Density in Confirmed Adult GH Deficiency

GH stimulates bone formation, partly through IGF-1, and raises bone mineral density in adults with confirmed AGHD. A meta-analysis found gains at the spine and hip in randomized or controlled studies lasting more than one year, while shorter studies showed a nonsignificant early drop ([Barake et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24423364/)). Gains were larger in men and in younger patients, and fracture reduction remains unproven in this group.

**Magnitude:** Lumbar spine bone mineral density +0.038 g/cm² (95% CI 0.011 to 0.065) and femoral neck +0.021 g/cm² (95% CI 0.006 to 0.037) in controlled studies longer than one year; significant in men but not in women.

### Medium 🟩 🟩

#### Cardiac Performance in Chronic Heart Failure

In chronic heart failure, GH thickened the heart wall, reduced chamber size and improved pumping and exercise tolerance. A meta-analysis combined 12 randomized and open-label trials ([Le Corvoisier et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17062772/)). Benefits tracked the IGF-1 response, and no large placebo-controlled outcome trial has followed.

**Magnitude:** Left ventricular ejection fraction (share of blood pumped per beat) +5.1 percentage points, NYHA class (New York Heart Association symptom scale from I to IV) −0.97, and exercise duration +104 seconds.

### Low 🟩

#### Fewer Fractures in Postmenopausal Osteoporosis ⚠️ Conflicted

Randomized trials in 272 postmenopausal women showed fewer fractures but no BMD (bone mineral density) gain ([Barake et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29030774/)). A 3-year Swedish trial found dose-dependent BMD gains ([Krantz et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26312576/)); pooled trials lasted 6–24 months. Net reading: a fracture benefit is possible but rests on few events.

**Magnitude:** Fracture RR (relative risk, risk in treated versus untreated) 0.63 (95% CI 0.46 to 0.87); no BMD change at spine or hip in the pooled trials.

#### Well-Being in Confirmed Adult GH Deficiency

Replacement in GH-deficient adults improves self-reported well-being. A meta-analysis of open-label studies found the largest effect on well-being and smaller effects on broader quality of life ([Deijen et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16236167/)). Lack of blinding likely inflates these estimates.

**Magnitude:** Effect size 0.47 for well-being (moderate), 0.18 for quality of life and 0.26 for health status (small).

#### Attention & Memory ⚠️ Conflicted

In healthy men over 69, one timed attention test improved while a global cognitive screen did not ([Papadakis et al., 1996](https://pubmed.ncbi.nlm.nih.gov/8633830/)). In GH-deficient adults, uncontrolled studies showed moderate attention and memory gains ([Falleti et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16621325/)). Net reading: benefit is plausible mainly with true deficiency.

**Magnitude:** Trail Making B time (a timed attention and task-switching test) improved by 13.5 seconds versus placebo (95% CI 3.1 to 23.9); no significant difference on the Mini-Mental State Examination (a brief cognitive screen).

#### Sprint Capacity ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

In 96 recreational athletes, eight weeks of GH raised sprint capacity but not strength or endurance, and the gain faded after stopping ([Meinhardt et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20439575/)). Pooled trials found no strength gain ([Liu et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18347346/)). This bears on athletic performance. Net reading: small and transient.

**Magnitude:** Sprint capacity +3.9% (95% CI 0.0 to 7.7%) with GH alone and +8.3% with GH plus testosterone in men.

### Speculative 🟨

#### Thymus Regrowth & Epigenetic Age Reversal

In nine men given GH, DHEA and metformin, thymic fat became active tissue and epigenetic clocks (DNA-methylation age estimates) fell ([Fahy et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31496122/)). This uncontrolled trial was sponsored by Fahy's company, Intervene Immune.

  

## Benefit-Modifying Factors

* **Genetic polymorphisms:** The exon-3-deleted GH receptor variant (d3-GHR, a common receptor form once thought more responsive) did not change IGF-1 or fat-loss response in 124 GH-deficient adults ([Barbosa et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19050057/)); no genotype predicts benefit.
* **Baseline IGF-1:** Benefits on exercise capacity, lipids and well-being are consistent only when IGF-1 is low because of confirmed pituitary deficiency; in healthy older men chosen for low IGF-1, body composition improved but function did not ([Papadakis et al., 1996](https://pubmed.ncbi.nlm.nih.gov/8633830/)).
* **Sex:** In older adults, men gained more lean mass than women (3.1 versus 1.0 kg with GH alone; [Blackman et al., 2002](https://pubmed.ncbi.nlm.nih.gov/12425705/)), and women on oral estrogen need roughly double the dose for the same IGF-1 ([Cook et al., 1999](https://pubmed.ncbi.nlm.nih.gov/10566634/)).
* **Pre-existing conditions:** Confirmed AGHD, chronic heart failure and postmenopausal osteoporosis are the settings with measurable benefit; people with normal pituitary function mainly see body-composition change.
* **Age:** Older adults respond to lower doses and remain in the age band where most healthy-volunteer trials were run (average age near 69); benefits beyond body composition are not established at the older end of the range.

  

## Potential Risks & Side Effects

<!-- Search statement: Before writing this section, a dedicated search for the complete side effect profile was performed on 2026-09-24 using US prescribing information for somatropin products (Genotropin, Norditropin, Humatrope) and drug references (drugs.com, Mayo Clinic), PubMed meta-analyses and RCTs (healthy elderly, athletes, adult GHD, critically ill patients), and long-term cohort data (SAGhE, manufacturer surveillance registries). Risks reviewed included edema, arthralgia, myalgia, carpal tunnel syndrome, gynecomastia, glucose intolerance and diabetes, critical-illness mortality, cancer, cerebrovascular events, intracranial hypertension, unmasking of hypothyroidism and adrenal insufficiency, acromegaly-like changes and overall mortality. -->

### High 🟥 🟥 🟥

#### Fluid Retention, Joint Pain, Carpal Tunnel Syndrome & Gynecomastia

GH causes the kidneys to retain sodium and water, producing edema (fluid swelling) of hands and feet, joint and muscle aches, and carpal tunnel syndrome (compression of the wrist nerve causing hand numbness). A meta-analysis of randomized trials in healthy older adults also found more gynecomastia (male breast enlargement) ([Liu et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17227934/)). These effects are dose-dependent and usually resolve with dose reduction, which 26% of treated older men needed ([Papadakis et al., 1996](https://pubmed.ncbi.nlm.nih.gov/8633830/)).

**Magnitude:** Edema 39% versus 0% in women on GH; arthralgia (joint pain) 41% versus 0% in men on GH; carpal tunnel symptoms 32% versus 0% in men on GH plus testosterone ([Blackman et al., 2002](https://pubmed.ncbi.nlm.nih.gov/12425705/)).

#### Impaired Glucose Tolerance & Type 2 Diabetes

GH opposes insulin action in liver and muscle and increases fat breakdown, raising blood glucose. In healthy older adults, GH produced more diabetes or glucose intolerance than placebo ([Blackman et al., 2002](https://pubmed.ncbi.nlm.nih.gov/12425705/)). A meta-analysis of 33 studies in GH-deficient adults showed rises in fasting glucose and HbA1c (average blood glucose over about three months) in the first year ([Zhou et al., 2021](https://pubmed.ncbi.nlm.nih.gov/32888174/)). In a Pfizer-sponsored surveillance registry, risk concentrated in heavier people with worse baseline metabolic profiles ([Luger et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22074727/)).

**Magnitude:** Diabetes or glucose intolerance in 18 GH-treated men versus 7 men not receiving GH; HbA1c SMD (standardized mean difference, a unit-free effect size) +0.31 at 6–12 months; diabetes incidence 2.6 per 100 patient-years (years of follow-up summed across all patients) in treated GH-deficient adults.

#### Higher Death Rate in Critical Illness

Two parallel RCTs gave high-dose GH to 532 adults in intensive care after heart or abdominal surgery, multiple trauma or respiratory failure ([Takala et al., 1999](https://pubmed.ncbi.nlm.nih.gov/10477776/)). Mortality roughly doubled, and survivors needed longer ventilation and hospital stays. The doses were far above replacement levels, but the finding bears on anyone using GH who becomes acutely and seriously ill.

**Magnitude:** In-hospital mortality 39% versus 20% in the Finnish trial and 44% versus 18% in the multinational trial; relative risk of death 1.9 and 2.4.

### Medium 🟥 🟥

#### Cerebrovascular & Circulatory Mortality

French registry data on 6,928 adults treated with GH in childhood showed excess deaths from circulatory disease and brain bleeding, and higher all-cause mortality at doses above 50 µg/kg per day ([Carel et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22238382/)). The full eight-country SAGhE cohort confirmed raised circulatory mortality across risk groups ([Sävendahl et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32707116/)). Adult-onset use has not been studied this way.

**Magnitude:** SMR (standardized mortality ratio, observed versus expected deaths) 3.07 for circulatory disease and 6.66 for subarachnoid or intracerebral hemorrhage (bleeding around or within the brain) in the French cohort.

### Low 🟥

#### Cancer Promotion ⚠️ Conflicted

Higher IGF-1 is associated with prostate and premenopausal breast cancer ([Renehan et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15110491/)). Childhood-treated cohorts show excess second tumors ([Deodati et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24818783/)), yet treated GH-deficient adults show fewer cancers ([Li et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27835910/)). Net reading: causation is unproven, but faster growth of existing tumors remains plausible.

**Magnitude:** OR (odds ratio, odds of disease with versus without exposure) 1.49 for prostate cancer comparing the 75th with the 25th IGF-1 percentile; second-tumor RR 1.99 after childhood treatment; cancer RR 0.69 in treated GH-deficient adults.

#### Accelerated Aging & Shorter Lifespan ⚠️ Conflicted

Both low and high IGF-1 predict higher mortality ([Burgers et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21795450/)), and in nonagenarian women lower IGF-1 predicted longer survival ([Milman et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24618355/)). Replacement in GH-deficient adults appears to normalize mortality ([van Bunderen & Olsson, 2023](https://pubmed.ncbi.nlm.nih.gov/37914564/)). Net reading: pushing IGF-1 above mid-range may shorten life.

**Magnitude:** HR (hazard ratio, relative rate of death over time) 1.29 comparing the 90th with the 50th IGF-1 percentile, and 1.56 comparing the 10th with the 50th.

#### Intracranial Hypertension

Intracranial hypertension (raised fluid pressure around the brain) causes headache, nausea and visual changes. A US Food and Drug Administration review of post-marketing reports described 13 cases in GH-treated children ([Malozowski et al., 1995](https://pubmed.ncbi.nlm.nih.gov/7776116/)). Most resolved after stopping GH; adult data are sparse.

**Magnitude:** Incidence 27.7 per 100,000 treatment-years (years on treatment summed across all children) among 57,968 GH-treated children in Pfizer's KIGS manufacturer database, from 12.2 in idiopathic GH deficiency to 147.8 in chronic renal insufficiency (reduced kidney function) ([Darendeliler et al., 2007](https://pubmed.ncbi.nlm.nih.gov/18174706/)); no adult incidence figure is reported.

### Speculative 🟨

#### Acromegaly-Like Tissue Overgrowth

Prolonged high dosing could reproduce acromegaly (the disease of GH excess), with enlarged jaw, hands, heart and organs. The basis is mechanistic, from mice overproducing GH ([Bartke, 2003](https://pubmed.ncbi.nlm.nih.gov/14583653/)) and isolated reports.

  

## Risk-Modifying Factors

* **Genetic polymorphisms:** No pharmacogenetic marker predicts GH side effects; inherited cancer-predisposition syndromes (for example BRCA1/2, genes that repair damaged DNA) raise theoretical concern about IGF-1-driven tumor growth.
* **Baseline biomarkers:** Higher body mass index, waist size, triglycerides and blood pressure predicted diabetes during treatment ([Luger et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22074727/)); baseline IGF-1 already in the upper age range leaves little margin before excess.
* **Sex:** In older adults, edema was most frequent in women, while joint pain, carpal tunnel symptoms and glucose intolerance clustered in men, especially with added testosterone ([Blackman et al., 2002](https://pubmed.ncbi.nlm.nih.gov/12425705/)).
* **Pre-existing conditions:** Prediabetes, prior cancer, heart failure, sleep apnea and pituitary disease (where GH can unmask low cortisol or thyroid hormone) raise risk; acute critical illness is the highest-risk state.
* **Age:** Older adults are more sensitive to fluid-related side effects; roughly a quarter of healthy men over 69 needed dose reduction at doses once considered physiologic ([Papadakis et al., 1996](https://pubmed.ncbi.nlm.nih.gov/8633830/)).

  

## Key Interactions & Contraindications

**Prescription drug interactions:**

* **Glucocorticoids (cortisol-like steroid medications: prednisone, hydrocortisone, dexamethasone):** Caution. GH lowers 11β-HSD1 activity (an enzyme that activates cortisol inside tissues), which can unmask adrenal insufficiency (too little cortisol); glucocorticoids also blunt GH effects. Morning cortisol testing detects this; replacement doses may need adjustment.
* **Insulin and glucose-lowering drugs (insulin, metformin, sulfonylureas, drugs that trigger insulin release, such as glipizide):** Monitor. GH raises blood glucose, weakening their effect and risking hyperglycemia (high blood sugar). Glucose and HbA1c rechecks after starting GH or changing its dose mitigate this.
* **Oral estrogen (oral estradiol, conjugated estrogens, oral contraceptives):** Monitor. Liver exposure to oral estrogen suppresses IGF-1 production, roughly doubling GH requirements. Switching to skin-patch or gel estradiol, or raising the GH dose stepwise to an IGF-1 target, restores response.
* **Thyroid hormone (levothyroxine, liothyronine):** Monitor. GH speeds conversion of T4 (thyroxine, the storage form) to T3 (triiodothyronine, the active form), lowering free T4 and possibly unmasking central hypothyroidism (low thyroid output from pituitary failure). Free T4 testing 1–3 months after starting detects this.
* **CYP3A4-cleared drugs (cyclosporine, carbamazepine, sex steroids, corticosteroids):** Monitor. GH may speed their clearance, lowering blood levels. Drug-level monitoring, such as pre-dose cyclosporine blood levels, after starting GH mitigates this.
* **Testosterone and anabolic steroids (testosterone enanthate, nandrolone):** Caution. Additive lean gain, but more carpal tunnel symptoms and glucose intolerance in older men. Lower GH doses are used when combined.

**Over-the-counter medication interactions:**

* **NSAIDs (non-steroidal anti-inflammatory drugs: ibuprofen, naproxen):** Monitor. Both promote sodium and water retention, adding to edema and blood-pressure rise. Limiting chronic daily use and tracking weight and ankle swelling mitigates this.
* **Extended-release niacin (nicotinic acid, sold over the counter):** Caution. Niacin raises blood glucose and insulin resistance, adding to GH's glucose effect. Fasting glucose and HbA1c monitoring mitigates this.

**Supplement interactions:**

* **GH secretagogues (drugs or peptides that trigger the body's own GH release: ibutamoren, ipamorelin, CJC-1295, high-dose arginine):** Caution. Additive IGF-1 elevation, edema and glucose rise. Avoiding stacking and adjusting doses to IGF-1 mitigates excess.
* **Licorice root (glycyrrhizin-containing):** Caution. Causes sodium retention and potassium loss, adding to GH-related edema and blood pressure. Deglycyrrhizinated licorice avoids this.
* **DHEA:** Monitor. Modestly raises IGF-1 and sex hormones; combined in the TRIIM protocol. IGF-1 and sex-hormone levels are tracked when combined.
* **Glucose-lowering supplements (berberine, chromium):** Monitor. May partly offset GH's glucose rise, which can mask worsening insulin resistance in home readings. HbA1c testing gives the full picture.

**Other intervention interactions:**

* **Prolonged fasting or very-low-protein diets:** Monitor. These reduce IGF-1 generation (a GH-resistant state), blunting response. IGF-1 is best measured on a normal diet.
* **Major surgery, trauma or intensive care admission:** Absolute contraindication during the acute phase. High-dose GH doubled mortality in critical illness. Suspending GH until recovery avoids this.

**Populations who should avoid HGH:**

* Active malignancy, or a cancer history without oncology clearance (especially within 5 years of treatment)
* Acute critical illness: complications after open-heart or abdominal surgery, multiple trauma, or acute respiratory failure
* Proliferative or severe non-proliferative diabetic retinopathy (diabetes-related damage to the retina's blood vessels)
* Uncontrolled diabetes (HbA1c ≥ 8%) or untreated diabetes (HbA1c ≥ 6.5%) without endocrine supervision
* IGF-1 already above the age-specific upper reference limit
* Pregnancy and breastfeeding
* Known hypersensitivity to somatropin or inactive product ingredients (for example metacresol)
* Children and adolescents outside an approved pediatric indication

  

## Risk Mitigation Strategies

* **Confirmation of need before starting:** Stimulation testing (glucagon or macimorelin test) separates true AGHD from normal age-related decline, avoiding edema, glucose and cancer risks where benefit is limited to body composition.
* **Low start with IGF-1-guided dose steps:** Protocols begin at 0.1–0.2 mg/day over age 60 (0.2–0.3 mg aged 30–60), increasing 0.1–0.2 mg every 4–8 weeks, to limit edema, joint pain and carpal tunnel syndrome.
* **Mid-range IGF-1 target:** Targeting the middle of the age-adjusted range (pooled mortality is lowest near 120–160 ng/mL; [Rahmani et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35048526/)) rather than youthful peaks mitigates the high-IGF-1 mortality and cancer signal.
* **Glucose surveillance:** Fasting glucose and HbA1c at baseline, 3 months, then every 6–12 months, with dose reduction if HbA1c rises ≥ 0.3 points, preventing progression to type 2 diabetes.
* **Up-to-date cancer screening:** Age-appropriate colonoscopy, mammography, PSA (prostate-specific antigen, a prostate blood marker) and skin checks before and during use reduce the chance of IGF-1 accelerating an undetected tumor.
* **Suspension during acute critical illness:** Stopping injections on admission for major surgery, trauma or intensive care avoids the doubled mortality seen with GH in critically ill patients.
* **Avoidance of above-natural dosing:** Staying well below bodybuilding doses (≥ 2 mg/day) limits acromegaly-like overgrowth and the higher all-cause mortality seen with high childhood doses.

  

## Therapeutic Protocol

* **Conventional endocrine protocol:** For confirmed AGHD, Endocrine Society guidance starts 0.4–0.5 mg/day under 30, 0.2–0.3 mg/day at 30–60 and 0.1–0.2 mg/day over 60, adjusted stepwise to IGF-1 ([Molitch et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21602453/)). Society members earn clinical income treating diagnosed deficiency.
* **Longevity-clinic protocol:** Edmund Chein and the American Academy of Anti-Aging Medicine popularized about 0.3–0.7 mg (1–2 international units) daily, often five days on and two off, targeting young-adult IGF-1; member clinics earn revenue prescribing hormones.
* **Thymus-regeneration protocol:** Greg Fahy's TRIIM regimen combines individually dosed somatropin with DHEA and metformin for 12 months, offsetting glucose effects; his company, Intervene Immune, sponsors the follow-up trial.
* **Indirect approaches:** Andrew Huberman popularized behavioral stimuli (deep sleep, high-intensity exercise, sauna) that raise the body's own GH pulses, and also discusses GH secretagogues (tesamorelin, ibutamoren), both avoiding constant exposure to injected hormone.
* **Time of day:** Most protocols inject subcutaneously at bedtime to mimic the natural night-time pulse tied to deep sleep; morning injection is an alternative when evening swelling is bothersome.
* **Half-life:** Daily GH has a half-life of about 2–4 hours after subcutaneous injection, but IGF-1 stays raised about a day; weekly long-acting forms (somapacitan) sustain IGF-1 with one injection.
* **Single versus split dosing:** A single daily injection is standard; split dosing offers no proven advantage, and five-on/two-off schedules lack comparative trials.
* **Genetic factors:** Receptor genotype (d3-GHR) did not alter response in GH-deficient adults, so no genetic test guides dosing; family cancer syndromes argue for conservative targets.
* **Sex differences:** Women, especially on oral estrogen, need higher doses (about 10.6 versus 5.0 µg/kg/day off oral estrogen and 4.1 µg/kg/day in men; [Cook et al., 1999](https://pubmed.ncbi.nlm.nih.gov/10566634/)); switching to skin-patch or gel estrogen lowers requirements.
* **Age:** Sensitivity rises with age, so adults over 60 start at 0.1–0.2 mg/day and increase slowly, with dose reduction if edema or joint pain appears.
* **Baseline biomarkers:** Low baseline IGF-1 predicts a larger IGF-1 rise per dose; high baseline glucose, HbA1c or body mass index predicts diabetes and calls for lower targets.
* **Pre-existing conditions:** In pituitary disease, cortisol and thyroid replacement are optimized first; heart failure, prior cancer and diabetes warrant specialist co-management.

  

## Discontinuation & Cycling

* **Lifelong versus short-term:** Confirmed AGHD replacement is usually long-term; longevity-oriented courses run 6–12 months, as in TRIIM, with no evidence defining optimal duration.
* **Withdrawal effects:** No dependence or withdrawal syndrome; gains reverse, with body fat rising from 31.5% to 33.8% over three years after stopping, mainly under age 60 ([Appelman-Dijkstra et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26944562/)).
* **Tapering-off protocol:** Tapering is not physiologically required; stopping abruptly is safe. IGF-1 is rechecked 4–8 weeks later, and glucose often improves.
* **Cycling:** No trial shows cycling preserves efficacy; replacement doses do not cause tolerance, and on/off schedules reflect clinic convention rather than evidence.

  

## Sourcing and Quality

* **Approved pharmaceutical products:** FDA (US Food and Drug Administration) or EMA (European Medicines Agency) approved somatropin: Genotropin (Pfizer), Norditropin (Novo Nordisk), Humatrope (Eli Lilly), Omnitrope (Sandoz), Saizen, Zomacton; weekly Sogroya, Skytrofa and Ngenla.
* **Biosimilars:** Omnitrope is an approved biosimilar (a near-identical copy of a biologic drug) with equivalent potency, usually at lower cost than originator brands.
* **What to look for:** Regulatory batch release replaces third-party testing for biologics, so sealed pharmacy-dispensed pens with lot numbers and cold-chain documentation are the quality marker.
* **No compounded GH:** Somatropin is a recombinant biologic that US compounding pharmacies cannot legally produce; "compounded HGH" signals an illegitimate supply chain.
* **Gray-market vials:** Unlicensed "research" powders are frequently underdosed, contaminated or counterfeit, and no independent testing program covers them.
* **Oral, spray and homeopathic products:** These contain no active GH, which is too large to be absorbed orally; at most they hold amino acids with brief effects on natural release.
* **Storage:** Products are refrigerated at 2–8 °C, never frozen and protected from light; reconstituted cartridges last 14–28 days depending on product.

  

## Practical Considerations

* **Time to effect:** IGF-1 rises within days and plateaus 1–2 weeks after a dose change; fat loss and lean gain are measurable at 3–6 months.
* **Common pitfalls:** Chasing youthful IGF-1 levels, stacking with secretagogues or testosterone, buying unlicensed product, skipping glucose checks, and expecting strength gains without resistance training.
* **Regulatory status (US):** Distributing GH for aging, bodybuilding or athletic use is a federal felony under 21 U.S.C. §333(e), unlike ordinary off-label prescribing. Approved adult uses include AGHD, HIV-associated wasting and short bowel syndrome (poor nutrient absorption after intestinal loss).
* **Regulatory status (sport and elsewhere):** WADA (World Anti-Doping Agency) bans GH in and out of competition; most countries restrict it to prescription for approved indications.
* **Cost and accessibility:** Branded somatropin commonly costs several hundred to several thousand US dollars monthly; insurers cover only confirmed deficiency, giving payers a financial incentive to favor strict diagnostic thresholds.
* **Injection logistics:** Daily subcutaneous pen injections require refrigeration and cold-chain planning for travel; weekly long-acting products reduce the burden.

  

## Interaction with Foundational Habits

* **Sleep:** Direct and bidirectional. Natural GH peaks in deep slow-wave sleep, and both decline sharply from early adulthood to midlife ([Van Cauter et al., 2000](https://pubmed.ncbi.nlm.nih.gov/10938176/)). Injected GH can worsen sleep apnea through fluid retention. Protecting deep sleep and avoiding bedtime alcohol support natural release.
* **Nutrition:** Potentiating and blunting. Adequate protein and energy intake sustain IGF-1 generation, while fasting raises GH but lowers IGF-1. Refined-carbohydrate-heavy diets add to GH's glucose rise; lower glycemic-load meals (meals that raise blood sugar less) limit it.
* **Exercise:** Indirect, no added strength. High-intensity and resistance exercise acutely raise GH, but injected GH did not increase strength gains from resistance training in older men ([Taaffe et al., 1994](https://pubmed.ncbi.nlm.nih.gov/7525633/)). Training remains the driver of strength and function.
* **Stress management:** Indirect. Chronic stress raises cortisol, which blunts GH action, while GH lowers active cortisol inside tissues and can unmask low cortisol in pituitary disease. Stress reduction supports deep sleep and natural GH pulses.

  

## Monitoring Protocol & Defining Success

Baseline testing before starting establishes deficiency status, metabolic risk and cancer-screening status: IGF-1 measured twice, a GH stimulation test where deficiency is suspected, fasting glucose, HbA1c, fasting insulin, lipid panel, free T4, morning cortisol, PSA in men, blood pressure and a DEXA body-composition scan (dual-energy X-ray absorptiometry, a low-dose X-ray body scan).

Ongoing monitoring follows a fixed cadence: IGF-1 at 4–8 weeks after each dose change, then every 6 months; fasting glucose and HbA1c at 3 months, then every 6–12 months; lipids and free T4 at 6 months, then yearly; PSA and DEXA yearly. Weight and home blood pressure are tracked weekly during the first 3 months to catch fluid retention early.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|---------------|
| IGF-1 | 120–200 ng/mL (middle of age-adjusted range) | Confirms dose; flags excess | Conventional range varies by age (roughly 50–250 ng/mL at 60); assay-specific; no fasting needed; pooled mortality lowest near 120–160 ng/mL |
| Fasting glucose | 70–90 mg/dL | Detects GH-induced hyperglycemia | Conventional normal < 100 mg/dL; 8–12 hour fast; morning draw |
| HbA1c | < 5.4% | Tracks average glucose | Conventional normal < 5.7%; best paired with fasting insulin |
| Fasting insulin | 2–6 µIU/mL | Early insulin resistance | Conventional upper limit about 25 µIU/mL; paired with glucose, it yields HOMA-IR (homeostatic model assessment of insulin resistance) |
| LDL cholesterol | < 100 mg/dL | Tracks lipid benefit | Conventional < 130 mg/dL; best paired with ApoB (apolipoprotein B, a count of plaque-forming particles) |
| Free T4 | 1.0–1.5 ng/dL | Detects unmasked hypothyroidism | Conventional about 0.8–1.8 ng/dL; TSH (thyroid-stimulating hormone) is unreliable in pituitary disease |
| Morning cortisol | 10–18 µg/dL | Detects unmasked adrenal insufficiency | Morning draw (8–9 a.m.); conventional about 5–23 µg/dL; most relevant in pituitary disease |
| PSA (men) | < 1.5 ng/mL and stable | Screens IGF-1-driven prostate growth | Conventional < 4.0 ng/mL; a rise > 0.75 ng/mL per year warrants review |
| Blood pressure and body weight | < 120/80 mmHg; weight stable | Detects fluid retention | Home readings; weight gain > 2 kg in a week suggests edema |
| DEXA body composition | No established target; rising lean mass and falling visceral fat versus own baseline | Measures main expected benefit | Change is tracked from the individual baseline; lean mass includes retained water |

**Qualitative markers:**

* Joint pain or morning stiffness in hands and knees
* Hand numbness or tingling, especially at night (carpal tunnel symptoms)
* Ankle swelling or rings becoming tight
* Energy, mood and sense of well-being
* Deep-sleep quality and snoring or apnea changes
* Exercise tolerance and recovery
* New headaches or visual changes

Success is defined as improved body composition and well-being with IGF-1 in the middle of the age-adjusted range, stable glucose and HbA1c, and no persistent side effects.

  

## Emerging Research

* **TRIIM-X thymus and epigenetic-age trial:** Phase 2, 85 participants, individually dosed somatropin with DHEA and metformin for 12 months; primary endpoints are GrimAge (a DNA-methylation mortality clock), thymic density and safety ([NCT04375657](https://clinicaltrials.gov/study/NCT04375657)). It extends [Fahy et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31496122/); the sponsor has commercial interests.
* **GH after acute brain injury in older adults:** Phase 4 multicenter RCT of 160 patients aged 60 or older with brain injury and low albumin; the primary endpoint is albumin change at week 2 ([NCT07481656](https://clinicaltrials.gov/study/NCT07481656)).
* **Tesamorelin plus exercise for frailty in HIV:** Phase 2, 100 participants, tests whether a GH-releasing hormone analog added to home exercise improves repeated chair-stand time ([NCT06554717](https://clinicaltrials.gov/study/NCT06554717)), an indirect route to raising GH.
* **Blocking GH action:** A Phase 2 NIH (US National Institutes of Health) trial of pegvisomant, a GH-receptor blocker, in 25 adults with severe insulin resistance tests the opposite hypothesis: that less GH signaling improves metabolism ([NCT05470504](https://clinicaltrials.gov/study/NCT05470504)).
* **Human low-GH-signaling cohorts:** Continued follow-up of the Ecuadorian GH-receptor-deficient ([Guevara-Aguirre et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21325617/)) and Brazilian GHRH-receptor-deficient (GHRH, the brain hormone that triggers GH release; [Aguiar-Oliveira & Bartke, 2019](https://pubmed.ncbi.nlm.nih.gov/30576428/)) cohorts may show whether lifelong low GH signaling extends healthy lifespan, which would weaken the case for supplementation.
* **Defining the optimal IGF-1 window:** Pooled cohorts place lowest mortality at 120–160 ng/mL ([Rahmani et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35048526/)); trials adjusting GH doses to this band, rather than to youthful levels, could test whether benefits persist without the mortality signal.
* **Targeted use in sick older adults:** A systematic review of eight RCTs ([Tausendfreund et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38489867/)) and a clinical review ([Fernández-Garza et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40260058/)) point toward trials with IGF-1-guided dosing in frail or ill older adults as the most promising direction.

  

## Conclusion

The manufactured form of human growth hormone reliably reshapes the body. It adds lean tissue and removes fat in healthy older adults and in people with a true shortage; in the latter it also improves fitness, cholesterol and bone density, and may lift well-being. In healthy older people this has not translated into greater strength or everyday function, and part of the added lean tissue is retained water.

The costs are consistent and appear quickly: swelling, joint pain, hand numbness and rising blood sugar that can progress to diabetes. Given during serious acute illness, it has sharply raised the risk of death. Longer-term effects are less certain. The hormone works largely through a growth signal made in the liver; long-lived animals and people with naturally weak signaling suggest that pushing it higher may trade near-term vigor for more cancer and a shorter life. Replacement in people with a true shortage, by contrast, appears to bring life expectancy back toward normal.

The evidence base is uneven. Much of the long-term safety tracking in adults comes from registries run by the drug's manufacturers. Hormone clinics and their professional academy, and the specialist societies whose members treat diagnosed shortage, each earn income from the positions they hold. The longevity-focused trials are small, short and partly company-funded. For health-focused adults with normal natural output, the evidence shows a visible body-composition gain set against a measurable metabolic cost, with effects on lifespan unresolved; for those with a confirmed shortage, the balance is considerably more favorable.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**